Marinus Shows Impressive Data In Depression Studies [Seeking Alpha]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Seeking Alpha
Marinus Shows Impressive Data In Depression StudiesSummaryMarinus Pharmaceuticals announced positive results from mid-stage study using IV ganaxolone to treat women with postpartum depression.Positive results were also announced for another mid-stage study treating women with postpartum depression but this time using oral ganaxolone.Additional results from both phase 2 studies, Magnolia and Amaryllis, are expected to be released by the 1st half of 2019.A competing pharmaceutical company by the name of Sage Therapeutics, working on the same indication, is expected to receive FDA approval for its postpartum depression drug ZULRESSO by March 19, 2019.Marinus has cash of $39.6 million which is expected to last into 2020; however, it is plausible that a cash raise could be done after a positive data release or by mid-2019.
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at HC Wainwright from $28.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $28.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEAccesswire
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Truist Financial Co. from $22.00 to $18.00. They now have a "hold" rating on the stock.MarketBeat
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website